表紙
市場調査レポート

腸疾患検査・治療:技術および世界市場

Enteric Disease Testing and Treatment: Technologies and Global Markets

発行 BCC Research 商品コード 316204
出版日 ページ情報 英文 210 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
腸疾患検査・治療:技術および世界市場 Enteric Disease Testing and Treatment: Technologies and Global Markets
出版日: 2014年10月14日 ページ情報: 英文 210 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の腸疾患診断・予防ワクチン市場額は2013年に65億米ドルに達しました。同市場は今後5年間27.3%のCAGRで拡大し、2014年に100億米ドル、2018年に219億米ドルに成長する見込みです。

当レポートでは、世界の腸疾患検査・治療市場について調査し、市場の概要、世界市場動向の分析、特定の病原菌または病原菌クラス向けの診断技術の最新の開発動向に関する情報、ポリメラーゼ連鎖反応(PCR)便検査の改善など業界に影響を及ぼす進歩の考察、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 腸疾患
    • ロタウィルス
    • チフス菌
    • エンテロトキシン産生大腸菌
    • コレラ菌
  • 腸内病原菌
  • 歴史的事実
  • 原因
  • 予防・管理
  • 下痢・病原菌
    • 2013 FOODNET REPORTからのハイライト
    • カンピロバクター菌
    • コレラ菌
    • サルモネラ菌
    • 大腸菌
    • チフス菌
    • ウイルス性病原菌
    • 寄生性病原体
  • 結論

第4章 腸疾患:生物学

  • 消化器官
  • 下痢のメカニズム
  • 様々な病原菌
  • 治療
  • 検査
  • 腸ワクチン

第5章 診断

  • 新しい診断法・影響評価
  • 主な感染症検査
  • 結論

第6章 治療

  • 急性腸管感染症
  • 新しい発展

第7章 発生率

  • 2012 FOODNET のデータ
  • 最近の取り組み・次のステップ
  • FOODCOREとは?
  • 下痢
  • チフス
  • シゲラ
  • カンピロバクター
  • コレラ
  • ノロウィルス
  • ロタウィルス
  • エンテロトキシン産生大腸菌
  • アメーバ症
  • 腸管寄生虫
  • クリプトスポリジウム
  • サマリー

第8章 腸疾患診断・検査市場

  • 腸疾患検査手法
  • 世界の腸疾患診断
  • 世界の腸疾患診断検査市場
  • 結論・CDCの提言

第9章 予防・治療市場

  • 腸疾患の治療市場
  • 現在の腸疾患の広がり
  • ワクチン:現在の市場力学
  • 結論

第10章 企業プロファイル

第11章 参考資料

目次
Product Code: HLC166A

REPORT HIGHLIGHTS

The global market for diagnostics and preventive vaccines for enteric diseases reached $6.5 billion in 2013. This market should grow to $10 billion in 2014 and about $21.9 billion in 2018, a compound annual growth rate (CAGR) of 27.3%.

This report provides:

  • An overview of the global market for enteric disease testing and treatment.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2018.
  • Information on recent developments in diagnostic technology for specific pathogens or classes of pathogens.
  • A look at how poor drainage and sanitation along with overcrowding and low hygiene awareness account for the majority of enteric infection incidences globally.
  • Insight into recent advances like improved stool polymerase chain reaction assays which are impacting the industry.
  • Comprehensive profiles of major players in the field.

SCOPE OF THE STUDY

The scope of this study are the clinical testing and preventative vaccine markets for enteric diseases. The report also includes the clinical segment, currently approved diagnostic tests and their markets, current testing technologies, new technologies, enteric diseases, causative agents and global incidence, market projections and market share along with the latest trends and new developments in this area. This report does not include the treatment market or the research market including reagents, instruments or any accessories used for diagnostic testing sample preparation or analysis. Other enteric pathogens or intestinal cancers are outside the scope of this report.

ANALYST'S CREDENTIALS

Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Her focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational costs and burdens.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR DIAGNOSTICS AND PREVENTIVE VACCINES FOR ENTERIC DISEASES, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR DIAGNOSTICS AND PREVENTIVE VACCINES FOR ENTERIC DISEASES, 2013-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • ENTERIC DISEASES
    • TABLE 1: COMMON CAUSAL AGENTS OF ENTERIC DISEASES
    • FIGURE 1: COMMON CAUSAL AGENTS OF ENTERIC DISEASES
  • ROTAVIRUS
    • Treatment
  • TYPHOID
  • ETEC AND SHIGELLA
  • CHOLERA
    • TABLE 2: GLOBAL EXISTENCE OF DIARRHEA
  • ENTERIC PATHOGENS
    • TABLE 3: PREVALENT ENTERIC DISEASE AND AGENTS
  • HISTORICAL FACTS
    • TABLE 4: MODERN/RECENT OUTBREAKS
  • CAUSES
    • TABLE 5: VIRUSES THAT CAUSE DIARRHEA
    • TABLE 6: BACTERIA THAT CAUSE DIARRHEA
    • TABLE 7: PARASITES THAT CAUSE DIARRHEA
  • PREVENTION AND CONTROL
    • EXAMS AND TESTS
      • TABLE 8: KEY MEASURES TO REDUCE THE NUMBER OF CASES OF DIARRHEA
      • Waterborne Diseases
        • TABLE 9: WATERBORNE CAUSES OF DIARRHEA
    • TREATMENT
    • PREVENTION
  • DIARRHEA AND PATHOGENS
    • TABLE 10: KEY POINTS
  • HIGHLIGHTS FROM THE 2013 FOODNET REPORT
    • TABLE 11: FOODNET CURRENT FINDINGS
  • CAMPYLOBACTER
    • TABLE 12: PREVENTION TECHNIQUES FOR CAMPYLOBACTER INFECTIONS
    • Spread of Campylobacter
  • CHOLERA
    • TABLE 13: CAUSATIVE PATHOGENS OF CHOLERA
    • TABLE 14: CLINICAL FEATURES OF CHOLERA
    • TABLE 15: TREATMENT: ANTIBIOTIC THERAPY
  • SALMONELLA
    • CDC Investigation Notice
  • ESCHERICHIA COLI
    • TABLE 16: STRAINS OF PATHOGENIC E. COLI
    • Shiga Toxin-Producing E. Coli
      • TABLE 17: PREVENTION TECHNIQUES FOR STEC INFECTIONS
    • Escherichia Coli (ETEC)
    • Recent News
  • TYPHOID
    • TABLE 18: TYPHOID SYMPTOMS
    • Typhoid Fever
      • TABLE 19: TWO LICENSED TYPHOID VACCINES
  • VIRAL PATHOGENS
    • Norovirus
      • Test to Detect Norovirus Outbreaks
      • Genetic Testing and Norovirus Resistance
  • PARASITIC PATHOGENS
    • Amebiasis
      • TABLE 20: OTHER ILLNESSES DUE TO E. HISTOLYTICA INFECTION
    • Life Cycle of Entamoeba Histolytica
    • Cryptosporidium
  • CONCLUSION

CHAPTER 4 - ENTERIC DISEASES: BIOLOGY

  • THE DIGESTIVE SYSTEM
    • DIGESTION
      • Carbohydrates
      • Protein
      • Fats
      • Vitamins
    • WHAT IS DIGESTION
      • TABLE 21: THE DIGESTIVE PROCESS
  • FOOD TRAVEL
    • Esophagus
    • Stomach
    • Small Intestine
    • Large Intestine
    • Digestion
    • Salivary Glands
    • Stomach Lining
    • Pancreas
    • Liver
  • SMALL INTESTINE
    • Process of Digestion
      • Hormones
      • Nerve Regulators
        • TABLE 22: KEY FACTORS IN DIGESTION
    • Intestinal Disorders
      • TABLE 23: PROBLEMS WITH THE SMALL INTESTINE
  • LARGE INTESTINE
    • TABLE 24: INTESTINAL PROBLEMS: COMMON CAUSES
    • Types of Intestinal Infections and Agents
      • TABLE 25: TYPES OF INFECTIONS AND AGENTS
    • Bacterial Infections
  • MECHANISMS OF DIARRHEA
    • TABLE 26: TYPES OF DIARRHEA
  • VARIOUS PATHOGENS
    • BACTERIAL INTESTINAL INFECTIONS
      • Escherichia Coli
      • Shigella
      • Salmonella
      • Clostridium Difficile
      • Helicobacter pylori
    • VIRAL INTESTINAL INFECTIONS
      • Rotavirus
      • Norovirus
    • PARASITIC INTESTINAL INFECTIONS
      • Giardiasis
  • TREATMENT
    • BACTERIAL INTESTINAL INFECTIONS
    • VIRAL GASTROENTERITIS
    • PARASITIC INTESTINAL INFECTIONS
      • Genetics vs Environment as Factors
        • TABLE 27: GENES INVOLVED IN ENTERIC DISEASES
      • Gut Immunity
    • PATHOPHYSIOLOGY
  • TESTS
  • ENTERIC VACCINES
    • DEVELOPING VACCINES AGAINST ENTERIC PATHOGENS
    • ESCHERICHIA COLI
      • TABLE 28: EVENTS THAT OCCUR UPON EXPOSURE TO SHIGELLA TOXIN

CHAPTER 5 - DIAGNOSIS

  • NOVEL DIAGNOSTICS AND IMPACT ASSESSMENT
    • DIAGNOSIS
      • TABLE 29: KEY FACTS OF DIARRHEA
      • Stool Cultures
        • TABLE 30: EXAMS AND TESTS FOR TYPHOID
        • TABLE 31: SHIGA TOXIN ANTIGEN TESTING IN CLINICAL MICROBIOLOGY LABORATORIES
  • OTHER DIAGNOSTIC TESTING
    • Complete Blood Count
    • Blood Cultures
    • Urinalysis
    • Imaging Studies
    • Blood Chemistry
    • Surgical Consultation
      • TABLE 32: DIAGNOSIS PROCESS
    • Molecular Diagnostics and Enteric Diseases
  • MAJOR INFECTIOUS DISEASE TESTS
    • TABLE 33: ENTEROPATHOGENS: CURRENT DIAGNOSTIC METHODS AND MOLECULAR TARGETS
  • TYPHOID DIAGNOSIS
    • TABLE 34: OUTLINE FOR THE DIAGNOSIS OF TYPHOID FEVER
    • Common Typhoid Tests
      • Widal Test
      • Culture
      • Stool Culture
      • Blood Culture
      • Bone Marrow Culture
      • Intestinal Secretion Culture
  • AMEBIASIS
    • TABLE 35: BASIC BLOOD TESTS: AMEBIASIS
    • Microscopy
    • Culture
    • Antigen Detection
    • Antibody Detection
    • Polymerase Chain Reaction Assay
    • Loop-Mediated Isothermal Amplification Assay
  • GASTROENTERITIS AND DIAGNOSIS
  • CAMPYLOBACTER SPP DETECTION
  • NOROVIRUS DIAGNOSTIC METHODS
    • RT-qPCR Assays
    • Conventional RT-PCR Assays for Genotyping
    • Enzyme Immunoassays
  • CLOSTRIDIUM DIFFICILE
  • OTHER VIRUSES
    • Parasites
    • Nondiarrheagenic Helminthes
    • Helicobacter Pylori
    • Infectious Esophagitis
  • EMERGING DIAGNOSTIC TECHNOLOGIES
    • TABLE 36: EMERGING DIAGNOSTIC TECHNOLOGIES FOR ENTERIC DISEASES
  • CONCLUSION

CHAPTER 6 - TREATMENT

  • TABLE 37: UNICEF/WHO: 7-POINT PLAN FOR DIARRHEAL DISEASE CONTROL
  • ACUTE ENTERIC INFECTIONS
    • TYPHOID AND PARATYPHOID FEVER
      • Oral Rehydration Therapy (ORT)
      • Treatment and Care
        • TABLE 38: TREATMENT AND CARE FOR DIARRHEA
        • TABLE 39: TREATMENT FOR MILD DIARRHEA
        • TABLE 40: TREATMENT FOR MODERATE DIARRHEA
        • TABLE 41: TREATMENT FOR MEDICALLY IMPORTANT DIARRHEA
        • TABLE 42: TREATMENT FOR SEVERE DIARRHEA
      • Nutrition and Zinc Supplements
        • TABLE 43: ANTIBIOTICS ASSOCIATED WITH COLITIS (AAC) TREATMENT
        • TABLE 44: ANTIBIOTICS ASSOCIATED WITH COLITIS (AAC) TREATMENT
      • Infectious Enteritis Due to Salmonella spp. Other than S. Typhi
      • Enteritis Due to Enterotoxigenic Escherichia Coli
  • AMEBIASIS
  • GIARDIASIS
  • CLOSTRIDIUM DIFFICILE
  • INTESTINAL TRACT AND TREATMENT
  • VACCINES
    • TABLE 45: UNLICENSED VACCINES
    • TABLE 46: ROTAVIRUS VACCINE
    • Enteric Vaccines: Summary
    • Vaccines for Enteric Diseases (VED 2013)
  • NEW DEVELOPMENTS
    • ACTOGENIX
    • CLOSTRIDIUM DIFFICILE-ASSOCIATED ENTERIC DISEASE
      • Proton Pump Inhibitors

CHAPTER 7 - INCIDENCE

  • 2012 FOODNET DATA
  • RECENT EFFORTS AND NEXT STEPS
  • WHAT IS FOODCORE
  • DIARRHEA
    • TABLE 47: PROPORTIONAL DISTRIBUTION OF DIARRHEA CASES AMONG CHILDREN UNDER FIVE YEARS OF AGE BY REGION, 2004 (MILLIONS)
    • TABLE 48: GLOBAL BURDEN OF ENTERIC DISEASES, 2013 (MILLIONS)
    • TABLE 49: KEY FACTS OF GLOBAL BURDEN OF DIARRHEAL DISEASES
    • TABLE 50: RISKS AND ETIOLOGIES OF GLOBAL BURDEN OF DIARRHEAL DISEASES
  • TYPHOID
    • UNITED STATES
    • GLOBAL INCIDENCE
      • TABLE 51: GLOBAL BURDEN OF TYPHOID EACH YEAR
  • SHIGELLA
    • UNITED STATES
    • GLOBAL INCIDENCE
      • TABLE 52: GLOBAL BURDEN OF SHIGELLA EACH YEAR (MILLIONS)
    • DEATH
  • CAMPYLOBACTER
    • UNITED STATES
    • GLOBAL INCIDENCE
      • TABLE 53: GLOBAL BURDEN OF CAMPYLOBACTER EACH YEAR (MILLIONS)
    • CONCLUSION
  • CHOLERA
    • TABLE 54: CLINICAL PRESENTATION RATES OF PATHOGENIC VIBRIO INFECTIONS (%)
  • GLOBAL STATISTICS
    • TABLE 55: GLOBAL BURDEN OF CHOLERA EACH YEAR (MILLIONS)
  • CHOLERA AND MORTALITY
    • NOROVIRUS
      • TABLE 56: GLOBAL BURDEN OF NOROVIRUS EACH YEAR (MILLIONS)
    • ROTAVIRUS
    • ENTEROTOXIGENIC E. COLI
      • TABLE 57: GLOBAL BURDEN OF ETEC EACH YEAR
  • AMEBIASIS
    • GLOBAL INCIDENCE
      • TABLE 58: GLOBAL BURDEN OF AMEBIASIS EACH YEAR (MILLIONS)
  • GIARDIA
    • NORTH AMERICA
    • GLOBAL INCIDENCE
  • CRYPTOSPORIDIUM
    • GLOBAL INCIDENCE
      • TABLE 59: GLOBAL BURDEN OF CRYPTOSPORIDIUM EACH YEAR (MILLIONS)
      • TABLE 60: MEANS FOR THE SPREAD OF CRYPTOSPORIDIUM PARASITES
  • SUMMARY
    • TABLE 61: KEY FACTS OF GASTROINTESTINAL INFECTIONS IN U.S.
    • TABLE 62: INDIVIDUAL PATHOGENS: NUMBER OF INFECTIONS AND U.S. INCIDENCE

CHAPTER 8 - ENTERIC DISEASE DIAGNOSTIC TESTING MARKET

  • ENTERIC DISEASE TESTING METHODS
    • TABLE 63: ENTERIC DISEASE TESTING METHODS
  • GLOBAL ENTERIC DISEASE DIGNOSTICS
    • TABLE 64: ENTERIC DISEASE DIAGNOSTICS BY TYPES OF DISEASES
  • STOOL TESTING
  • TYPICAL COSTS
    • TABLE 65: ENTERIC TESTING COSTS
  • GLOBAL MARKET FOR ENTERIC DIAGNOSTIC TESTS
    • TABLE 66: GLOBAL MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, THROUGH 2018 ($ MILLIONS)
    • FIGURE 2: GLOBAL MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, 2013-2018 ($ MILLIONS)
  • U.S. MARKET FOR ENTERIC DISEASES
    • TABLE 67: U.S. MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, THROUGH 2018 ($ MILLIONS)
    • FIGURE 3: U.S. MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, 2013-2018 ($ MILLIONS)
  • TYPHOID
    • TABLE 68: TYPHOID TESTS
    • TABLE 69: TYPHOID TESTS DETAILS
    • TABLE 70: SEROLOGIC TESTS FOR TYPHOID
    • Diagnostic Tests Market
      • TABLE 71: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 4: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • Treatment Costs
      • Provider and Public Treatment Costs
  • CHOLERA
    • Diagnosis and Detection
      • TABLE 72: TYPES OF CHOLERA TESTS ON THE MARKET
    • Future
    • Impact of Cholera
    • New Developments
      • Rapid Diagnostic Test
      • Detection: U.S.
      • Diagnostic Tests Market
        • TABLE 73: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 5: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
  • CLOSTRIDIUM DIFFICILE
    • Stool Tests
      • TABLE 74: C. DIFFICILE TESTS
    • Colon Examination
    • Imaging Tests
  • CAMPYLOBACTER DIAGNOSTIC TESTS
    • Techniques
      • TABLE 75: CAMPYLOBACTER TESTS
    • Diagnostic Tests Market
      • TABLE 76: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 6: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 77: U.S. MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 7: U.S. MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
  • E. COLI DIAGNOSIS
    • Diagnostic Tests Market
      • TABLE 78: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 8: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 79: U.S. MARKET FOR E. COLI DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 9: U.S. MARKET FOR E. COLI DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • CDC Recommendations for Detecting STEC Infection
  • GIARDIASIS
    • Diagnostic Tests Market
      • TABLE 80: GLOBAL MARKET FOR GIARDIA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 10: GLOBAL MARKET FOR GIARDIA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 81: U.S. MARKET FOR GIARDIA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 11: U.S. MARKET FOR GIARDIA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
  • CRYPTOSPORIDIOSIS DIAGNOSTIC TESTS
    • Diagnostic Tests Market
      • TABLE 82: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 12: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 83: U.S. MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 13: U.S. MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • Other Methods
      • TABLE 84: FEATURES OF THE CRYPTOSPORIDIUM KIT FROM GENESIG
  • AMEBIASIS DETECTION TESTS
    • Microscopy
    • Culture
    • Antigen Detection
    • Antibody Detection
    • Polymerase Chain Reaction Assay
    • Loop-Mediated Isothermal Amplification Assay
    • Diagnostic Tests Market
      • TABLE 85: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 14: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 86: U.S. MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 15: U.S. MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
  • SHIGELLA LABORATORY TESTS
    • Diagnostic Tests Market
      • TABLE 87: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 16: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 88: U.S. MARKET FOR SHIGELLA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 17: U.S. MARKET FOR SHIGELLA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • Stool Examination
    • Stool Culture
    • Rapid Techniques
  • NOROVIRUS DIAGNOSTIC METHODS
    • RT-qPCR Assays
    • Conventional RT-PCR Assays for Genotyping
    • Enzyme Immunoassays
    • Diagnostic Tests Market
      • TABLE 89: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 18: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 90: U.S. MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 19: U.S. MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
  • ROTAVIRUS TESTS
    • Diagnostic Tests Market
      • TABLE 91: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 20: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
      • TABLE 92: U.S. MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 21: U.S. MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
  • CONCLUSIONS AND CDC RECOMMENDATIONS

CHAPTER 9 - PREVENTION AND TREATMENT MARKET

  • TREATMENT MARKET FOR ENTERIC DISEASES
    • ANTIBIOTIC MARKET
    • THERAPEUTICS
    • VACCINES MARKET
      • TABLE 93: MAJOR VACCINES
      • TABLE 94: GLOBAL PREVENTIVE VACCINE MARKET, ESTIMATES THROUGH 2018 ($ MILLIONS)
      • TABLE 95: GLOBAL ADULT VACCINE MARKET, ESTIMATES THROUGH 2018 ($ MILLIONS)
      • TABLE 96: TOTAL PEDIATRIC VACCINE MARKET, ESTIMATES, 2013 AND 2014 ($ MILLIONS)
      • TABLE 97: OTHER VACCINES MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 98: MAJOR COMPETITORS IN THE GLOBAL VACCINES MARKET
    • CURRENT SPREAD OF ENTERIC DISEASES
    • VACCINES: CURRENT MARKET DYNAMICS
      • TABLE 99: GLOBAL MARKET FOR ENTERIC DISEASE VACCINES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 22: GLOBAL MARKET FOR ENTERIC DISEASE VACCINES, 2013-2018 ($ MILLIONS)
    • TYPHOID
      • TABLE 100: GLOBAL TYPHOID VACCINE MARKET, THROUGH 2018 ($ MILLIONS)
      • TABLE 101: TYPHOID VACCINES ON THE MARKET
      • TABLE 102: ESTIMATED COSTS OF THE TYPHOID VACCINE IN THE U.S.
    • CHOLERA
      • TABLE 103: GLOBAL MARKET FOR CHOLERA VACCINE, THROUGH 2018 ($ MILLIONS)
      • TABLE 104: DEVELOPMENT OF BACTERIAL VACCINES, HISTORICAL PERSPECTIVE
      • TABLE 105: CURRENTLY LICENSED VACCINES
    • CAMPYLOBACTER INFECTIONS
    • NOROVIRUS INFECTION
    • ROTAVIRUS VACCINE
      • TABLE 106: ROTAVIRUS VACCINE KEY FACTS
      • TABLE 107: VACCINATION SCHEDULE
        • Rotarix
        • RotaTeq
      • TABLE 108: COMPARISON OF ROTAVIRUS VACCINES
      • Revenue
        • TABLE 109: GLOBAL MARKET FOR ROTAVIRUS VACCINES, THROUGH 2018 ($ MILLIONS)
        • FIGURE 23: GLOBAL MARKET FOR ROTAVIRUS VACCINES, 2012-2018 ($ MILLIONS)
      • RRV-TV (Rotashield)
        • TABLE 110: CURRENTLY LICENSED ROTAVIRUS VACCINES
  • NEXT STEPS/DEVELOPMENTS IN VACCINES
    • TABLE 111: NEW ENTERIC DISEASE VACCINES IN DEVELOPMENT
    • Cholera Vaccines in Development
    • Typhoid Vaccines in Development
    • New Developments
      • TABLE 112: VACCINES IN DEVELOPMENT
  • TRAVEL VACCINES
    • TABLE 113: TRAVEL VACCINES MARKET, 2012 AND 2013 ($ MILLIONS)
    • ETEC AND SHIGELLA
      • Shigellosis
      • Environmental Enteric Dysfunction (Gut Dysfunction)
      • Killed Whole-Cell Vaccines
  • CONCLUSIONS

CHAPTER 10 - COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ACTOGENIX NV
  • AFFYMETRIX
  • ASTELLAS PHARMA INC.
  • BAYER
  • BECKMAN COULTER INC.
  • BECTON DICKINSON AND COMPANY
  • BHARAT BIOTECH
  • BIOMERIEUX
  • BIO-RAD LABORATORIES
  • BRISTOL-MYERS SQUIBB CO.
  • CEPHEID
  • CRUCELL
  • DAIICHI SANKYO INC.
  • ELI LILLY & CO.
  • GLAXOSMITHKLINE
  • JOHNSON & JOHNSON
  • IDL BIOTECH
  • MERCK & CO.
  • NOVARTIS CORP.
  • PFIZER
  • QUEST DIAGNOSTICS
  • R-BIOPHARM AG
  • RESZON DIAGNOSTICS INTERNATIONAL
  • ROCHE
  • SANOFI
  • SPAN DIAGNOSTICS
  • TAKEDA PHARMACEUTICAL CO.
  • IMPORTANT NON-PROFIT SOURCES
    • BILL & MELINDA GATES FOUNDATION
    • CHILD HEALTH EPIDEMIOLOGY REFERENCE GROUP
    • GAVI ALLIANCE SECRETARIAT
    • PAN AMERICAN HEALTH ORGANIZATION

CHAPTER 11 - REFERENCES

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR DIAGNOSTICS AND PREVENTIVE VACCINES FOR ENTERIC DISEASES, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: COMMON CAUSAL AGENTS OF ENTERIC DISEASES
    • TABLE 2: GLOBAL EXISTENCE OF DIARRHEA
    • TABLE 3: PREVALENT ENTERIC DISEASE AND AGENTS
    • TABLE 4: MODERN/RECENT OUTBREAKS
    • TABLE 5: VIRUSES THAT CAUSE DIARRHEA
    • TABLE 6: BACTERIA THAT CAUSE DIARRHEA
    • TABLE 7: PARASITES THAT CAUSE DIARRHEA
    • TABLE 8: KEY MEASURES TO REDUCE THE NUMBER OF CASES OF DIARRHEA
    • TABLE 9: WATERBORNE CAUSES OF DIARRHEA
    • TABLE 10: KEY POINTS
    • TABLE 11: FOODNET CURRENT FINDINGS
    • TABLE 12: PREVENTION TECHNIQUES FOR CAMPYLOBACTER INFECTIONS
    • TABLE 13: CAUSATIVE PATHOGENS OF CHOLERA
    • TABLE 14: CLINICAL FEATURES OF CHOLERA
    • TABLE 15: TREATMENT: ANTIBIOTIC THERAPY
    • TABLE 16: STRAINS OF PATHOGENIC E. COLI
    • TABLE 17: PREVENTION TECHNIQUES FOR STEC INFECTIONS
    • TABLE 18: TYPHOID SYMPTOMS
    • TABLE 19: TWO LICENSED TYPHOID VACCINES
    • TABLE 20: OTHER ILLNESSES DUE TO E. HISTOLYTICA INFECTION
    • TABLE 21: THE DIGESTIVE PROCESS
    • TABLE 22: KEY FACTORS IN DIGESTION
    • TABLE 23: PROBLEMS WITH THE SMALL INTESTINE
    • TABLE 24: INTESTINAL PROBLEMS: COMMON CAUSES
    • TABLE 25: TYPES OF INFECTIONS AND AGENTS
    • TABLE 26: TYPES OF DIARRHEA
    • TABLE 27: GENES INVOLVED IN ENTERIC DISEASES
    • TABLE 28: EVENTS THAT OCCUR UPON EXPOSURE TO SHIGELLA TOXIN
    • TABLE 29: KEY FACTS OF DIARRHEA
    • TABLE 30: EXAMS AND TESTS FOR TYPHOID
    • TABLE 31: SHIGA TOXIN ANTIGEN TESTING IN CLINICAL MICROBIOLOGY LABORATORIES
    • TABLE 32: DIAGNOSIS PROCESS
    • TABLE 33: ENTEROPATHOGENS: CURRENT DIAGNOSTIC METHODS AND MOLECULAR TARGETS
    • TABLE 34: OUTLINE FOR THE DIAGNOSIS OF TYPHOID FEVER
    • TABLE 35: BASIC BLOOD TESTS: AMEBIASIS
    • TABLE 36: EMERGING DIAGNOSTIC TECHNOLOGIES FOR ENTERIC DISEASES
    • TABLE 37: UNICEF/WHO: 7-POINT PLAN FOR DIARRHEAL DISEASE CONTROL
    • TABLE 38: TREATMENT AND CARE FOR DIARRHEA
    • TABLE 39: TREATMENT FOR MILD DIARRHEA
    • TABLE 40: TREATMENT FOR MODERATE DIARRHEA
    • TABLE 41: TREATMENT FOR MEDICALLY IMPORTANT DIARRHEA
    • TABLE 42: TREATMENT FOR SEVERE DIARRHEA
    • TABLE 43: ANTIBIOTICS ASSOCIATED WITH COLITIS (AAC) TREATMENT
    • TABLE 44: ANTIBIOTICS ASSOCIATED WITH COLITIS (AAC) TREATMENT
    • TABLE 45: UNLICENSED VACCINES
    • TABLE 46: ROTAVIRUS VACCINE
    • TABLE 47: PROPORTIONAL DISTRIBUTION OF DIARRHEA CASES AMONG CHILDREN UNDER FIVE YEARS OF AGE BY REGION, 2004 (MILLIONS)
    • TABLE 48: GLOBAL BURDEN OF ENTERIC DISEASES, 2013 (MILLIONS)
    • TABLE 49: KEY FACTS OF GLOBAL BURDEN OF DIARRHEAL DISEASES
    • TABLE 50: RISKS AND ETIOLOGIES OF GLOBAL BURDEN OF DIARRHEAL DISEASES
    • TABLE 51: GLOBAL BURDEN OF TYPHOID EACH YEAR
    • TABLE 52: GLOBAL BURDEN OF SHIGELLA EACH YEAR (MILLIONS)
    • TABLE 53: GLOBAL BURDEN OF CAMPYLOBACTER EACH YEAR (MILLIONS)
    • TABLE 54: CLINICAL PRESENTATION RATES OF PATHOGENIC VIBRIO INFECTIONS (%)
    • TABLE 55: GLOBAL BURDEN OF CHOLERA EACH YEAR (MILLIONS)
    • TABLE 56: GLOBAL BURDEN OF NOROVIRUS EACH YEAR (MILLIONS)
    • TABLE 57: GLOBAL BURDEN OF ETEC EACH YEAR
    • TABLE 58: GLOBAL BURDEN OF AMEBIASIS EACH YEAR (MILLIONS)
    • TABLE 59: GLOBAL BURDEN OF CRYPTOSPORIDIUM EACH YEAR (MILLIONS)
    • TABLE 60: MEANS FOR THE SPREAD OF CRYPTOSPORIDIUM PARASITES
    • TABLE 61: KEY FACTS OF GASTROINTESTINAL INFECTIONS IN U.S.
    • TABLE 62: INDIVIDUAL PATHOGENS: NUMBER OF INFECTIONS AND U.S. INCIDENCE
    • TABLE 63: ENTERIC DISEASE TESTING METHODS
    • TABLE 64: ENTERIC DISEASE DIAGNOSTICS BY TYPES OF DISEASES
    • TABLE 65: ENTERIC TESTING COSTS
    • TABLE 66: GLOBAL MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, THROUGH 2018 ($ MILLIONS)
    • TABLE 67: U.S. MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, THROUGH 2018 ($ MILLIONS)
    • TABLE 68: TYPHOID TESTS
    • TABLE 69: TYPHOID TESTS DETAILS
    • TABLE 70: SEROLOGIC TESTS FOR TYPHOID
    • TABLE 71: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 72: TYPES OF CHOLERA TESTS ON THE MARKET
    • TABLE 73: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 74: C. DIFFICILE TESTS
    • TABLE 75: CAMPYLOBACTER TESTS
    • TABLE 76: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 77: U.S. MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 78: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 79: U.S. MARKET FOR E. COLI DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 80: GLOBAL MARKET FOR GIARDIA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 81: U.S. MARKET FOR GIARDIA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 82: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 83: U.S. MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 84: FEATURES OF THE CRYPTOSPORIDIUM KIT FROM GENESIG
    • TABLE 85: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 86: U.S. MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 87: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 88: U.S. MARKET FOR SHIGELLA DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 89: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 90: U.S. MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 91: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 92: U.S. MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 93: MAJOR VACCINES
    • TABLE 94: GLOBAL PREVENTIVE VACCINE MARKET, ESTIMATES THROUGH 2018 ($ MILLIONS)
    • TABLE 95: GLOBAL ADULT VACCINE MARKET, ESTIMATES THROUGH 2018 ($ MILLIONS)
    • TABLE 96: TOTAL PEDIATRIC VACCINE MARKET, ESTIMATES, 2013 AND 2014 ($ MILLIONS)
    • TABLE 97: OTHER VACCINES MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 98: MAJOR COMPETITORS IN THE GLOBAL VACCINES MARKET
    • TABLE 99: GLOBAL MARKET FOR ENTERIC DISEASE VACCINES, THROUGH 2018 ($ MILLIONS)
    • TABLE 100: GLOBAL TYPHOID VACCINE MARKET, THROUGH 2018 ($ MILLIONS)
    • TABLE 101: TYPHOID VACCINES ON THE MARKET
    • TABLE 102: ESTIMATED COSTS OF THE TYPHOID VACCINE IN THE U.S.
    • TABLE 103: GLOBAL MARKET FOR CHOLERA VACCINE, THROUGH 2018 ($ MILLIONS)
    • TABLE 104: DEVELOPMENT OF BACTERIAL VACCINES, HISTORICAL PERSPECTIVE
    • TABLE 105: CURRENTLY LICENSED VACCINES
    • TABLE 106: ROTAVIRUS VACCINE KEY FACTS
    • TABLE 107: VACCINATION SCHEDULE
    • TABLE 108: COMPARISON OF ROTAVIRUS VACCINES
    • TABLE 109: GLOBAL MARKET FOR ROTAVIRUS VACCINES, THROUGH 2018 ($ MILLIONS)
    • TABLE 110: CURRENTLY LICENSED ROTAVIRUS VACCINES
    • TABLE 111: NEW ENTERIC DISEASE VACCINES IN DEVELOPMENT
    • TABLE 112: VACCINES IN DEVELOPMENT
    • TABLE 113: TRAVEL VACCINES MARKET, 2012 AND 2013 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR DIAGNOSTICS AND PREVENTIVE VACCINES FOR ENTERIC DISEASES, 2013-2018 ($ MILLIONS)
    • FIGURE 1: COMMON CAUSAL AGENTS OF ENTERIC DISEASES
    • FIGURE 2: GLOBAL MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, 2013-2018 ($ MILLIONS)
    • FIGURE 3: U.S. MARKET FOR DIAGNOSTIC TESTS FOR ENTERIC DISEASES, 2013-2018 ($ MILLIONS)
    • FIGURE 4: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 5: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 6: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 7: U.S. MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 8: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 9: U.S. MARKET FOR E. COLI DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 10: GLOBAL MARKET FOR GIARDIA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 11: U.S. MARKET FOR GIARDIA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 12: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 13: U.S. MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 15: U.S. MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 16: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 17: U.S. MARKET FOR SHIGELLA DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 18: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 19: U.S. MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 21: U.S. MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, 2013-2018 ($ MILLIONS)
    • FIGURE 22: GLOBAL MARKET FOR ENTERIC DISEASE VACCINES, 2013-2018 ($ MILLIONS)
    • FIGURE 23: GLOBAL MARKET FOR ROTAVIRUS VACCINES, 2012-2018 ($ MILLIONS)
Back to Top